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Abstract 
There is a growing body of evidence supporting the association between 
inflammation and major depressive disorder (MDD). One plausible mechanism for this 
association is sensitization of the immune response, possibly due to prior exposure to 
stressors. To investigate the validity of this hypothesis, a series of three complimentary 
cross-species studies was conducted. Study 1 examined the associations between 
circulating levels of inflammatory markers and in vitro immune reactivity with women’s 
history of recurrent MDD (rMDD) and their current symptoms of anhedonia. The 
potential moderating role of women’s history of childhood abuse was also examined.  
Study 2 and 3 focused on animal models of the influence of adolescent stress on LPS-
induced changes in adult anhedonic behavior (Study 2) and inflammatory gene 
expression in brain areas associated with reward processing and stress (Study 3). 
Although there was no evidence of increased circulating or stimulated levels of 
inflammation among women’s history of rMDD in Study 1, current level of anhedonia 
was associated with increased stimulated levels of inflammatory markers. Results of 
Study 2 showed a marginally significant trend for the effect of adolescent stress exposure 
on anhedonia-like behavior in adult rats, such that rats subjected to an acute stressor in 
adolescence showed a decreased preference for palatable substance (sucrose) as adults. 
Finally, the results of Study 3 provided no support for altered neuroinflammatory 
response in the brain areas related to reward processing and stress based on the 
adolescent stress exposure. Overall, the findings highlight the importance for integration 
  
of interdisciplinary methodology in psychological studies, yield initial support for the 
role of the immune system in anhedonia and provide important directions for future 
research.  
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Depression and Inflammation 
Major depressive disorder (MDD) is the leading cause of disability worldwide 
(“WHO | Depression,” 2016), with 10% of men and 20% of women in the U.S. 
experiencing at least one episode of MDD during their lives (Vos et al., 2012). 
Additionally, up to 60% of individuals who experience an initial MDD episode are 
expected to relapse following recovery and the risk of recurrence increases with each 
subsequent episode (Bulloch, Williams, Lavorato, & Patten, 2014; Solomon et al., 2000). 
Recurrent MDD (rMDD) is characterized by distinct genetic, neurobiological, and 
hormonal profiles compared to a single MDD episode (sMDD; Admon et al., 2014; 
Levinson et al., 2003), carries a greater risk for more adverse and chronic 
consequences,(Burcusa & Lacono, 2007; Lewinsohn, Allen, Seeley, & Gotlib, 1999), and 
is less responsive to antidepressant medication (Kaymaz, van Os, Loonen, & Nolen, 
2008).  
Although multiple neural mechanisms are likely to contribute to depression 
susceptibility later in life, a rapidly growing body of research suggests that immune-
derived signaling factors, such as pro-inflammatory cytokines, play an important role in 
the pathogenesis of depression.  For example, otherwise healthy individuals with MDD 
display elevated peripheral and cerebrospinal fluid (CSF) levels of inflammatory immune 
markers (e.g., IL-6, IL-1β, C-reactive protein; Dowlati et al., 2010; Ford & Erlinger, 
2004; Levine et al., 1999; Liu, Ho, & Mak, 2012). In addition, individuals suffering from 
chronic and acute inflammatory conditions demonstrate increased levels of inflammatory  
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markers and depressive symptoms (Capuron et al., 2002; Musselman et al., 2001; Owen, 
Eccleston, Ferrier, & Young, 2001). Furthermore, up to 50% of patients undergoing 
cytokine immunotherapy develop MDD (Miller, Maletic, & Raison, 2009). Moreover, 
animals that were administered inflammatory cytokines demonstrate sickness behavior, 
which closely resembles the depressive phenotype in humans (Miller & Raison, 2016). 
Finally, higher levels or circulating inflammatory markers in childhood prospectively 
predicted greater risk of developing depression and psychopathology in adulthood 
(Khandaker, Pearson, Zammit, Lewis, & Jones, 2014).  
Several cytokines have emerged from previous research as strong candidates for 
playing a significant role in MDD, including IL-1β, IL-6, IL-1β, and IL-10 (Anisman, 
Ravindran, Griffiths, & Merali, 1999; Dowlati et al., 2010; Goshen & Yirmiya, 2009; 
Mesquita et al., 2008; Omrani et al., 2009).  IL-6 has emerged as one of the strongest 
candidates from several meta-analyses that examined human studies of inflammatory 
processes and depression (Dowlati et al., 2010; Howren, Bryant, Lamkin, & Suls, 2009; 
Liu et al., 2012). Recent evidence suggests that one of the ways in which IL-6 impacts 
neurotransmission and subsequent behavior is by exerting direct regulatory control over 
serotonin transporter (SERT) activity, potentially linking this cytokine to one of the 
hypothesized mechanisms underlying the development and maintenance of depression 
Delgado (2000). Providing additional support for this link, there is evidence that IL-6 
leads to decreases in mRNA and protein levels of SERT in vitro and in vivo (Kong et al., 
2015). Conversely, the hippocampal tissue of mice lacking IL-6 expression (IL-6 KO) 
has been shown to contain increased levels of SERT, which corresponded to decreased 
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depression-like behaviors and blunted response to antidepressant medication (Kong et al., 
2015). 
 Another cytokine that has been frequently implicated in MDD and depression-
like behavior is IL-1β. An ample body of human and translational animal research 
suggests that MDD and depression-like behavior are frequently accompanied by 
increased levels of IL-1β (Michael Maes, Song, & Yirmiya, 2012). As with IL-6, IL-β 
has been shown to modulate SERT levels (Zhu, Blakely, & Hewlett, 2006), and mediate 
the effects of changes in SERT activity on subsequent depression-like behavior following 
exposure to a common pathogen, lipopolysaccharide (LPS), that it typically used in 
research to induce the immune response (Zhu et al., 2010). 
 Each of the cytokines reviewed thus far are proinflammatory cytokines and are 
associated with T helper 1 cells (Th1).  In addition to these, there is evidence that Th2 
cytokines, or anti-inflammatory cytokines, including IL-10, also play a role in MDD and 
depression-like behaviors, such that the circulating levels of IL-10 increase following 
anti-depressant treatment (Tavakoli-Ardakani, Mehrpooya, Mehdizadeh, Hajifathali, & 
Abdolahi, 2015). Providing further support for the role of IL-10 in MDD and depression-
like behavior, Mesquita et al. (2008) showed that IL-10 knockout (KO) mice displayed 
increased depression-like behaviors, while mice that overexpressed IL-10 evidenced 
decreased depression-like behaviors. Moreover, systemic IL-10 administration has been 
shown to decrease depression-like behavior in rodents (Mesquita et al., 2008). Lastly, 
similarly to IL-6 and IL-1β, IL-10 has been shown to alter SERT levels. Specifically, 
high concentrations of IL-10 has been shown to induce SERT production in vitro, while 
low levels of IL-10 decrease SERT production (Latorre et al., 2013).  
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 In addition to these well-established cytokines, there is growing evidence for the 
potential role of IL-33 in depression.  IL-33 is a multifunctional ligand within the IL-1 
superfamily (Baekkevold et al., 2003; Schmitz et al., 2005). By binding to the ST2 
receptor, the ligand for which remained unknown until 2005, (Ali et al., 2007; Schmitz et 
al., 2005), IL-33 activates nuclear factor kappa B (NF-κB) and p38 mitogen-activated 
protein kinases (MAPK), culminating in altered expression of downstream pro-
inflammatory cytokines, chemokines, and anti-inflammatory cytokines (Allakhverdi, 
Smith, Comeau, & Delespesse, 2007; Kakkar & Lee, 2008; Mirchandani, Salmond, & 
Liew, 2012; Moulin et al., 2007; Yasuoka et al., 2011). Thus, IL-33 appears to be 
embedded within key signaling pathways that are already known to link cytokine 
signaling with MDD. Additionally, previous research suggests the involvement of IL-33 
in neuroinflammatory processes (Chapuis et al., 2009; Yu et al., 2012) and bipolar 
disorder (Barbosa et al., 2014). There is also preliminary evidence that IL-33 may 
increase risk for rMDD. Specifically, our laboratory previously examined whether 
naturally occurring variation in the IL-33 and IL-1β genes would moderate the link 
between women’s history of childhood abuse and their risk for MDD. We found that, 
among women with a history of childhood abuse, the protective IL-33 CT haplotype was 
associated with their history of rMDD. We also found that circulating IL-33 and IL-1β 
levels were significantly higher among women with rMDD than among women with a 
single MDD episode (sMDD) and women with no history of depression. Additionally, we 
expanded the project to the CNS using rat brain tissue. We found that an acute stressor 
increased IL-33 expression in the paraventricular nucleus of the hypothalamus (PVN) 
and, to a lesser extent, the rat analogue of the prefrontal cortex (PFC). In combination, 
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these results provide preliminary evidence for the role of IL-33 in stress response and risk 
for rMDD.  Given the aforementioned findings, this proposal aims to focus on IL-6, IL-
1β, IL-10, and IL-33 in the context of depression.  
In addition to examining the association between circulating levels of 
inflammatory markers and depression diagnosis and symptoms, researchers developed a 
paradigm in which a stimulated in vitro cytokine response in peripheral blood 
mononuclear cells (PBMCs) to an immune stressor is measured. Early studies that 
employed this paradigm reported greater levels of induced IL-1β and IL-6 among 
psychiatric inpatients with MDD (Maes et al., 1993), compared to never depressed 
controls. However, interpretation of these findings is complicated by multiple factors that 
could impact immune functioning, including changes in usual diet, sleep schedule, and 
additional stress levels, which are all associated with inpatient hospitalization (Weizman 
et al., 1994). Similar studies conducted with outpatients with current MDD report 
increased production of inflammatory cytokines following an in vitro challenge with 
cortisol and dexamethasone (Heiser, Lanquillon, Krieg, & Vedder, 2008). To capture the 
potential association between history of rMDD and both ambient levels of peripheral 
inflammatory markers as well as the magnitude of a cytokine response to an immune 
challenge, we aimed to assess both circulating and stimulated levels of IL-1β, IL-6, IL-10 
and IL-33. 
In addition to examining the presence of depression generally, there is evidence 
that inflammation may play a key role in specific depressive symptoms suggesting the 
possible existence of different biological subtypes of MDD (Holtzheimer & Mayberg, 
2011). Although only a small number of studies examined the effects of inflammation on 
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MDD features that go beyond somatic and vegetative symptoms (Slavich & Irwin, 2014), 
this growing body of literature suggests that inflammation could be particularly 
associated with symptoms of anhedonia. For instance, inflammation was shown to affect 
functional connectivity within reward neurocircuitry among patients with current MDD, 
such that higher circulating levels of CRP, IL-1β, IL-1RA, and IL-6 were associated with 
decreased connectivity in corticostriatal reward and motor neurocircuitry (Felger et al., 
2015), suggesting that inflammation may play an important role in motor deficits and 
decreased motivation observed in depressed individuals. Moreover, an endotoxin-
stimulated decrease in the activity of the ventral striatum, a key brain region involved in 
reward processing, mediated the link between increased circulating levels of 
inflammatory markers and depressed mood among adult participants with no history of 
chronic medical or psychiatric conditions (Eisenberger et al., 2010). Together, these 
finding point to an association between both circulating and induced inflammation levels 
and reward circuitry underlying anhedonia. Activity in the reward-processing network 
commonly referred to as the mesolimbic dopamine circuit that connects ventral tegmental 
area and nucleus accumbens, has been strongly linked to manifestations of anhedonia and 
depressive symptoms in previous research (Heshmati & Russo, 2015). However, these 
studies examined inflammation and depressive symptoms without isolating anhedonia 
symptoms, and whether the levels of inflammatory markers are associated specifically 
with current anhedonia symptoms remains unclear. This is important, as there is a 
growing recognition of the need to study dimensional constructs underlying core features 
of psychopathology as opposed to focusing on specific diagnoses (Carcone & Ruocco, 
2017; Zalta & Shankman, 2016). Additionally the presence of anhedonia is hypothesized 
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to play a critical role in developing treatment resistant depression and is predictive of 
poor response to first-line antidepressant treatments in prospective clinical studies (Uher 
et al., 2012). Therefore, the project examined the association between circulating and 
stimulated cytokines and current levels of anhedonia among women. 
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Early Life Stress, Inflammation, and Depression 
Stress is a well- known risk factor for depression (e.g., Hammen, 2005) and has 
been strongly linked to lasting changes in the inflammatory processes (Slavich & Irwin, 
2014). For example, exposure to childhood adversity, including abuse, neglect, and low 
socioeconomic status, prospectively predicted greater levels of inflammation in adulthood 
(Danese, Pariante, Caspi, Taylor, & Poulton, 2007; Raposa, Bower, Hammen, Najman, & 
Brennan, 2014; Slopen et al., 2010).  In parallel, findings from rodent models of early life 
stress support the link between early life stress exposure and abnormal immune function, 
including immune over-activation assessed via hippocampal IL-1β expression, later on in 
life (Kanitz, Tuchscherer, Puppe, Tuchscherer, & Stabenow, 2004; Llorente et al., 2007; 
Stiller, Drugan, Hazi, & Kent, 2011). One of the biological pathways for the link between 
early life stress and MDD is through the sensitization of the immune responses (Anisman, 
Merali, & Hayley, 2003; Hymie Anisman, Merali, & Hayley, 2008; Michael Maes, Berk, 
et al., 2012). Intriguingly, exposure to early life stress may also impact the link between 
inflammation and depression. For example, depressed adults who also had a history of 
childhood abuse had greater levels of inflammatory markers compared to adults with no 
history of childhood abuse (Danese et al., 2008). In addition, early life stress moderated 
the magnitude of inflammatory responses to a laboratory-based stressor later in life, such 
that participants with a history of childhood abuse displayed greater levels of 
inflammatory markers following the stressor, compared to individuals
with no history of abuse (Carpenter et al., 2010). Together, these findings provide 
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evidence for altered stress-induced immune responding among those exposed to early life 
stress.  What remains unclear is whether the alterations in immune functioning persist 
after full remission of depression and could be detected among participants with a history 
of rMDD with no current depression diagnosis. Additionally, whether or not history of 
childhood abuse would moderate this association is unknown. To fill this gap, the current 
project will examine the association between cytokine reactivity following an immune 
challenge and rMDD history and the potential moderating effect of childhood abuse 
history on this link. 
Previously described literature points to the link between early life stress and 
inflammation and connects inflammation to anhedonia. The next question then focuses on 
whether early life stress impacts anhedonia later in life. Intriguingly, findings from cross-
sectional neuroimaging studies in humans show that history of childhood adversity was 
associated with greater current anhedonia symptoms, particularly among individuals who 
evidenced low levels of activation in the ventral striatum during a reward-focused task 
(Corral-Frías et al., 2015), suggesting that exposure to stress may have a prolonged affect 
on depressive symptoms. Animal studies, which generally allow assessment of causality, 
show that exposure to early life stress and chronic prenatal stress may lead to increased 
depression-like behaviors in adulthood (Ślusarczyk et al., 2015; Wohleb et al., 2012). 
Multiple paradigms have been developed to assess depression-like behaviors in studies 
utilizing animal models of depression, including those measuring animal’s socialization, 
locomotion, spatial exploration, swimming, and preference for appetitive foods. 
Measuring preference for a sucrose solution, which is highly palatable to rodents, over 
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regular water is commonly used to assess anhedonia, a core symptom of depression, in 
animals (Der-Avakian & Markou, 2012). 
Increase in depression-like behaviors, including anhedonia, can also be observed 
following an exposure to an immune challenge, such as a systemic administration of a 
known endotoxin, including LPS, to produce a robust immune response (Bison et al., 
2009). Indeed, previous research suggests that LPS-stimulated anhedonia, expressed by a 
decrease in preference for sucrose, is one of the defining features of animal models of 
depression (De La Garza, 2005; Frenois et al., 2007). Although some previous studies 
found an increase in depression-like behaviors in mice following injections of LPS 
(Bison et al., 2009), others have failed to find any effects of LPS on depression-like 
behaviors (Deak et al., 2005). For instance, Deak et al. (2005) report no depressogenic 
effects of LPS administration on behavior during a subsequent forced swim test (FST) in 
rats. This could be partly due to differences in behavioral tests that were used to assess 
depression-like behaviors. To clarify previous findings, this project used a well-
established measure of anhedonia-like behavior, the sucrose preference paradigm 
(O’Connor et al., 2009; Smolinsky, Bergner, LaPorte, & Kalueff, 2009). Additionally, the 
effect of the immune challenge in adult animals could be greatly enhanced by early life 
stress exposure. Therefore, building on previously mentioned findings regarding the 
impact of early life-stress on depression-like behaviors, we aimed to examine whether 
exposure to an adolescent stressor would impact behavioral responses, specifically 
sucrose preference, to an immune challenge in adulthood.  
Findings from research focusing on biological sequalae of stress in the brain, 
typically conducted in rodents, suggests that exposure to stress leads to time and region-
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dependent neuroinflammation. For example, exposure to an acute stressor via exogenous 
stress hormone administration generated a robust neuroinflammatory response in the key 
structures comprising the HPA axis in adult rats (Hueston & Deak, 2014). Similarly, 
chronic stress has been noted to lead to microglia activation and increase in inflammatory 
markers in the brain (for review, see Calcia et al., 2016). For example, repeatedly 
restrained adult rats evidenced increased number and activation in immune cell 
population (microglia) in stress-sensitive areas, including amygdala, paraventricular 
nucleus of the hypothalamus, nucleus accumbens, and hippocampus (Tynan et al., 2010). 
Another study that examined the time course of chronic stress-induced alterations in the 
immune system showed increased microglia activation following the first few days of 
stress exposure, which was followed by a decrease in a number of immune cells in the 
prefrontal cortex and hippocampus, suggesting that chronic stress could contribute to 
reduction in neurogenesis observed among depressed individuals (Kreisel et al., 2013). 
Stress exposure at an earlier age appears to have similar effects on the immune processes, 
as repeatedly socially defeated adolescent mice evidenced elevated and prolonged 
induction of IL-1β and TNF-α and microglia activation in the amygdala, paraventricular 
nucleus of the hypothalamus, prefrontal cortex, and hippocampus, following a subsequent 
immune challenge (Wohleb et al., 2012). Similarly, prenatal stress resulted in greater 
microglia activation in the rat prefrontal cortex and hippocampus, as well as increased 
levels of inflammatory markers, including IL-1β, IL-6, IL-18, TNF-α in microglia 
cultures. Moreover, these alterations in immune responses were associated with increase 
in depression-like behaviors, including decreased sucrose preference and prolonged 
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social withdrawal and among rodents subjected to stressors (Kreisel et al., 2013; Wohleb 
et al., 2012).  
What remains unclear is whether early life stress affects neuroimmune responses 
to stress in brain regions associated with stress and anhedonia, a key symptom of 
depression, in adulthood. Given the previously mentioned findings from neuroimaging 
studies in humans linking peripheral inflammation with changes in connectivity in the 
brain regions underlying reward processing, animal studies showing the relation between 
early life stress and immune processes in the brain, we further extended the scope of our 
investigation to examine the role of early life stress in neuroinflammatory responses in 
the brain regions comprising a reward processing network to an immune challenge in 
adulthood. 
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Specific Aims of the Present Investigation 
The overarching goal of the current study was to examine the association between 
inflammatory markers and depression. The project was comprised of a series of human 
and translational animal studies and employed interdisciplinary, cross-species assessment 
methods. This allowed us to capitalize on the strength of both human and animal research 
methodology to build a comprehensive investigation that examined research questions 
ranging from cross-sectional associations to prospective causality and underlying 
biological mechanisms (Figure 1).  
In Study 1, we examined (a) the concentration of circulating cytokines and (b) 
levels of cytokines released from stimulated peripheral blood mononuclear cells 
(PBMCs) in vitro, which allowed us to overcome both technical and conceptual 
limitations associated with either technique alone. Thus, Study 1 focused on examining 
the association between women’s history of rMDD and circulating and stimulated levels 
of cytokines (IL-1β, IL-6, IL-10, and IL-33). We hypothesized that women with a history 
of rMDD would evidence increased levels of both circulating and stimulated 
inflammatory markers compared to participants with no depression history. Additionally, 
Study 1 aimed to examine whether the link between history of rMDD and circulating and 
stimulated levels of cytokines was moderated by women’s history of childhood abuse. 
We hypothesized that, among women with a history of rMDD, those who were also 
abused as children would evidence the highest levels of circulating and stimulated 
inflammatory markers. To begin to examine immune processes linked to different
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 depressive phenotypes, Study 1 also explored whether participants’ current levels of 
anhedonia were associated with increased levels of circulating and stimulated cytokines 
(IL-1β, IL-6, IL-10, and IL-33). Exploratory analyses were also conducted to examine the 
potential association between anhedonia and other cytokines produced by monocytes and 
macrophages (e.g., Th-17 cytokines), which were selected due to their role in maintaining 
the balance between immunity and inflammation and involvement in the pathogenesis of 
multiple inflammatory and autoimmune conditions characterized by increased anhedonia 
(Guglani & Khader, 2010). 
Studies 2 and 3 sought to extend the results of Study 1 to an animal model of 
depression.  The goal of Study 2 was to examine whether exposure to stressors in 
adolescence would affect anhedonia-like behavior following exposure to an in vivo 
immune challenge in adulthood. A well-established sucrose preference paradigm was 
used to index anhedonia-like behavior in rats. We hypothesized that rats exposed to 
stressors in adolescence would evidence greater levels of anhedonia-like behavior 
following an immune challenge. Additionally, we aimed to assess two distinct challenges 
during adolescence on later adhedonia-like behavior in adulthood. Specifically, we 
investigated the potential effect of the number of stress exposures (chronic vs. single) as 
well as variation in the stressor type (combination of restraint, forced swim, and acute 
footshock vs. acute footshock only). Although a single exposure to a severe stressor has 
been shown to induce depression-like phenotype in rodents (Chu et al., 2016), chronic 
stress paradigms are generally considered to have greater translational potential and the 
outcomes more closely resemble depressive symptoms in humans (Strekalova et al., 
2011; Willner, 2017). Therefore, we included both types of stress paradigms to compare 
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the magnitude of their potential effect on adhedonia-like behavior. Specifically, one 
group of rats went through the Chronic Escalating Stress paradigm developed by Deak 
and colleagues (Doremus-Fitzwater, Paniccia, Gano, Vore, & Deak, 2018), which 
incorporates the use of several stressors that gradually increase in severity. The other 
group was subjected to a single exposure to a severe stressor (AFS).  
Finally, Study 3 examined whether mRNA levels of IL-1β, IL-6, IL-33, and IL-10 
were modulated in brain areas underlying reward processing and stress reactivity (i.e., 
nucleus accumbens [NAc], ventral tegmental area [VTA], amygdala [AMG], and the 
paraventricular nucleus of the hypothalamus [PVN]) following an in vivo immune 
challenge in adult rats with and without a history of adolescent stress. We hypothesized 
that adult rats with a history of adolescent stress exposure would evidence higher 
cytokine gene (IL-1β, IL-6, IL-10 and IL-33) expression in response to an LPS challenge 
in adulthood in the NAc, VTA, AMG, and PVN, compared to animals without a history 
of adolescent stress exposure or saline-injected rats. As in Study 2, we used two types of 
stress paradigms (chronic escalating stress vs. acute). 
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Study 1 
This study investigated whether rMDD would be associated with potentiated 
immune reactivity. Based on our laboratory’s earlier research suggesting that altered 
cytokine reactivity may be more strongly associated with rMDD than sMDD (Kudinova 
et al., 2017), we focused on immune reactivity of participants with a history of rMDD 
versus those with no lifetime depression. We collected biological samples from adult 
human participants in an ongoing study (R01 HD057066; PI: Gibb).  
Method 
Participants and Procedure. Participants were 39 adults recruited from the 
community as part of a larger study of depression and anxiety in children (Table 1). 
Participants were required to either have a history of recurrent MDD (rMDD; n = 20) or 
have no lifetime history of MDD (n = 19).  The average age of participants was 36.81 
years (SD = 7.55) and the majority were women (87.2%). In terms of race/ethnicity, the 
majority were Caucasian (76.3%) and the rest were African American (15.8%), 
Asian/Pacific Islander
 (2.6 %), or from other racial/ethnic groups (5.3%). The median annual family income 
was between $45,001 and $50,000. Upon arrival at the laboratory, participants were 
asked to provide informed consent and then administered the SCID-I. Following this, 
participants completed questionnaires. Finally, peripheral blood samples, height, weight, 
and body temperature were collected. Blood samples of the majority of participants 
(66.7%) were collected between 3-7PM and the rest were collected between 9AM -2PM. 
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All participants were compensated $80 for their participation in the larger project, which 
was approved by the university’s institutional review board. 
Clinical diagnoses. The Structured Clinical Interview for DSM Disorders (SCID-I) (First, 
Spitzer, Gibbon, & Williams, 2002) was used to assess for lifetime histories of DSM-IV 
psychiatric disorders. The SCID-I is a widely used diagnostic interview with well-
established psychometric properties (First et al., 2002). A subset of 20 SCID-I interviews 
was coded by a second interviewer and interrater reliability for diagnoses of MDD was 
excellent (κ = 1.00). Out of 39 participants, 20 women (51.3%) had a history of rMDD in 
this study. Distribution of lifetime occurrences of other diagnoses was a follows: Alcohol 
Use Disorder = 14 (35.9%), Post-Traumatic Stress Disorder (PTSD) = 9 (23.1%), Panic 
Disorder (PD) = 8 (20.5%), Social Phobia (SP) = 6 (15.4%), Substance Use Disorder = 6 
(15.4%), Obsessive Compulsive Disorder (OCD) = 4 (10.3%), and Generalized Anxiety 
Disorder (GAD) = 4 (10.3%). Of those women, the distribution of participants who met 
criteria for current diagnoses was as follows: PD = 6 (15.4%), GAD = 4 (10.3%), SP = 3 
(7.7%), OCD = 2 (5.1%), MDD = 2 (5.1%), and PTSD = 1 (5.1%). 
Childhood abuse history. The Childhood Trauma Questionnaire (CTQ; 
Bernstein, Ahluvalia, Pogge, & Handelsman, 1997) was used to assess participants' 
histories of childhood emotional, physical, and sexual abuse. In this population sample, 
CTQ exhibited good to excellent internal consistency (emotional abuse α = .92, physical 
abuse α = .84, sexual abuse α = .91). Using the established cutoffs on the CTQ (Bradley 
et al., 2014), moderate levels of abuse were defined as an emotional abuse (EA) subscale 
score greater than 12, a physical abuse (PA) subscale score greater than 9, and/or sexual 
abuse (SA) subscale score greater than 7. Of the women in our sample, 4 reported EA 
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only (10.3%), 1 reported PA only (2.6%), 6 reported SA only (15.4%), 2 reported EA and 
SA (5.1%), 3 reported PA and SA (7.7%), none reported EA and PA, and 4 reported all 
three types of abuse (10.3%). Consistent with prior research using the CTQ (Rebekah G. 
Bradley et al., 2008), women were coded as having a history of no or mild abuse (n = 19) 
or having a history of moderate to severe levels of abuse (n = 20). Thirteen (65%) 
participants with a history of CA also had a history of rMDD and 7 (35%) did not. Seven 
(36.8%) participants with no history of CA had a history of rMDD and 12 (63.2%) had no 
history of either CA or rMDD. 
Anhedonia symptoms. Levels of anhedonia were assessed using the anhedonic 
depression subscale of the Mood and Anxiety Symptom Questionnaire (MASQ; Kendall 
et al., 2015). This is a well-established measure of anhedonia that demonstrated good 
reliability and validity in previous research (Bredemeier et al., 2010), with higher scores 
reflecting greater levels of symptomatology. In this sample, the MASQ-AD subscale 
exhibited excellent internal consistency (α = .92).  
Depressive symptoms. The Beck Depression Inventory-II (BDI-II) was used to 
assess women’s levels of current depressive symptoms (Beck, Steer, & Brown, 1996). 
This measure demonstrated good reliability and validity in previous research (Arnau, 
Meagher, Norris, & Bramson, 2001) and showed good internal consistency in the current 
sample (α = .88). 
Circulating cytokine levels. Whole blood was collected via BD Vacutainer Blood 
Collection Sets into 4.0 mL tubes, coated with ethylenediaminetetraacetic acid (EDTA). 
Plasma was separated by centrifugation (1000 × g for 10 min at 4° C) and stored at –
80°C. We used the Bio-Plex Pro Human Cytokine Panel (171-AA001M) and Bio-Plex 
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MAGPIX system to assay IL-1β, IL-6, IL-10, and IL-33 concentrations (Bio-Rad, 
Philadelphia, PA). MAGPIX system is a magnetic bead-based multi-analyte fluorescent 
detection system. Each sample was run in triplicate. The average intra- assay coefficients 
of variation were as follows: IL-1β = 5.0%, IL-6 = 5.4%, IL-10 = 3.8%, IL-33 = 4.2%. 
The average inter- assay coefficients of variation were as follows: IL-1β = 2.7%, IL-6 = 
4.4%, IL-10 = 1.7%, IL-33 = 8.6%. The lower limits of quantification were as follows:  
IL-1β = 0.24 pg/mL, IL-6 = 1.65 pg/mL, IL-10 = 1.99 pg/mL, IL-33 = 4.18 pg/mL. 
Circulating levels of IL-1β for the majority of our participants (97.4%) were below the 
detection limit of our assay and we therefore excluded IL-1β from all subsequent 
analyses related to peripheral levels of inflammation. Values for the other three cytokines 
were not normally distributed and were log transformed.  
Cytokine reactivity. We followed a well-established protocol for conducting an 
in vitro lipopolysaccharide (LPS) immune challenge (e.g., Schildberger, Rossmanith, 
Eichhorn, Strassl, & Weber, 2013). Whole blood was collected by certified phlebotomists 
using BD Vacutainer Blood Collection Sets into BD Vacutainer Cell Preparation silicon-
coated 4.0 mL tubes with sodium citrate. PBMCs were isolated and stored using 
previously described methods (Mallone et al., 2011). Briefly, PBMCs were separated by 
centrifugation (1500 × g for 20 minutes at 23± 1ºC) and washed three times in phosphate 
buffered saline (PBS) suplemented with 10% fetal bovine serum (FBS, Fisher Scientific, 
Pittsburg, PA). The cells were re-suspended in RPM Media-1640 with 10% dimethyl 
sulfoxide sterile solution (DMSO, Sigma-Aldrich, St. Louis, MO) and 20% FBS and 
placed into a Coolcell® freezing container (Biocision, San Rafael, CA), which was kept 
in a –80 ºC freezer for 12h. After that, cryo vials with cells were transferred into liquid 
  20 
nitrogen storage until furter testing. The average cell survival rate was > 98.00%, which 
is comparable or higher than the rates obtained in previous research (Mallone et al., 
2011).  On the day of the testing, a fraction of the cells from each sample (10 μl) were 
stained with Trypan Blue Stain solution (Thermo Fisher Scientific, Waltham, MA) and 
the live/dead cells were counted via a hemocytometer. Cells were then pelleted by 
centrifugation at 250 × g and re-suspended in 10% cell-culture grade Fetal Bovine Serum 
(Seradigm Life Sciences, Philadelphia, PA) and LPS-enriched RPMI 1640 media 
(Invitrogen, Waltham, MA) containing at 1 × 106 cells/mL and incubated for 24h at 37 
ºC. LPS concentration (10 ng/mL) and duration were selected based on recommendations 
from previous research (Schildberger et al., 2013). After 24h, the cells were pelleted by 
centrifugation (2000 rpm for 5 min) and the supernatants removed and stored at –80°C.  
Levels of IL-1β, IL-6, IL-10, and IL-33 protein were subsequently measure using Bio-
Plex Pro Human TH17 Cytokine assay (Bio-Rad, Philadelphia, PA). The average intra- 
assay coefficients of variation were as follows: IL-1β = 5.7%, IL-6 = 4.0%, IL-10 = 
5.1%, IL-33 = 2.5%. The average inter- assay coefficients of variation were as follows: 
IL-1β = 3.8%, IL-6 = 3.0%, IL-10 = 2.5%, IL-33 = 3.3%. The lower limits of 
quantification were as follows:  IL-1β = 0.24 pg/mL, IL-6 = 1.65 pg/mL, IL-10 = 1.99 
pg/mL, IL-33 = 4.18 pg/mL. Values for all cytokines were not normally distributed and 
were log transformed. Levels of stimulated cytokines were not significantly associated 
with the levels of corresponding circulating cytokines (lowest p = .81). 
Total Protein Concentration.  Total plasma protein concentrations were 
assessed via bicinchoninic acid (BCA) protein assay (Thermo Fisher Scientific, Waltham, 
MA). The lower limit of quantification was 20 ug/mL. The average inter and intra- assay 
  21 
coefficients of variation were both below 1%. All circulating and stimulated cytokine 
values were normalized to the total protein levels, as recommended by previous research 
(Ber et al., 2014; Collins, An, Peller, & Bowser, 2015; Hepworth et al., 2012). 
Lifetime smoking history.  Participants’ lifetime smoking history was assessed 
using the modified version of the Semi-Structured Assessment of the Genetics of 
Alcoholism (SSAGA; Bucholz et al., 1994), which is a comprehensive psychiatric 
interview used to assess physical, psychological, social, and psychiatric manifestations of 
alcohol abuse or dependence and other psychiatric disorders in adults. Modifications 
were introduced to collect data on maternal smoking and drinking patterns during 
pregnancy (Knopik et al., 2005). Similarly to previous research (Kudinova et al., 2016), 
participants were dichotomized based on their smoking history into a group that smoked 
100 or more cigarettes in their lifetime and those who smoked less. 
Physiological Measures. To control for potential confounding effects of 
participants’ Body Mass Index (BMI) and body temperature, participants’ height and 
weight were measured for BMI calculation. Body temperature was measured by sliding 
the probe of an infrared thermometer across the participant’s forehead (Exergen, 
Watertown, MA). 
Results  
Circulating cytokine levels.  To examine whether circulating levels of IL-6, IL-
10, and IL-33 were linked to participants’ history of rMDD, we conducted a series of 
ANOVAs using circulating levels of each of the cytokines (IL-6, IL-10, and IL-33) as a 
dependent variable and rMDD history as an independent factor. There was no significant 
rMDD group differences for any of the three cytokines: IL-6, F(1, 38) = 0.87, p = .36, η2 
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= .02, IL-10, F(1, 38) = 0.33, p = .57, η2 = .01, or IL-33, F(1, 38) = 0.16, p = .69, η2 = 
.004 (Figure 2).  
Following this, to test whether women’s history of CA moderated the relation 
between participants’ history of rMDD and their circulating cytokine levels, we ran a 
series of ANOVAs using circulating levels of each cytokine (IL-6, IL-10, and IL-33) as a 
dependent variable and rMDD, CA, and the rMDD × CA interaction as independent 
factors. We found a significant main effect of CA history on circulating levels of IL-6, 
F(1, 38) = 4.00, p = .05, η2 = .10, but not IL-10, F(1, 38) = .02, p = .90, η2 < .001, or IL-
33, F(1, 38) = 0.50, p = .48, η2 = .01, with participants reporting a history of CA 
exhibiting greater levels of circulating IL-6 (M = 0.03 log pg/mg) compared to 
participants with no CA history (M = 0.01 log pg/mg; Figure 3). The rMDD × CA 
interaction was not significant for any of the cytokines: IL-6, F(1, 38) = 0.49, p = .49, η2 
= .01, IL-10, F(1, 38) = 0.23, p = .63, η2 = .01, or IL-33, F(1, 38) = 0.10, p = .75, η2 = 
.003. The results remained unchanged, for the most part, when we excluded participants 
with a current MDD diagnosis (n = 2), men (n = 5), or both (n = 6). Please see Study 1 
supplementary data section for detail. 
Stimulated cytokines. To test our hypotheses regarding cytokine reactivity, we 
again ran a series of ANOVAs with reactivity for each of the cytokines (IL-1β, IL-6, IL-
10, and IL-33) as a dependent variable and rMDD history as an independent factor. We 
found no significant main effect of rMDD history on stimulated levels of IL-1β, F(1, 38) 
= 0.24, p = .88, η2 = .001, IL-6, F(1, 38) = 0.002, p = .96, η2 < .001, IL-10, F(1, 38) = 
0.77, p = .39, η2 = .02, or IL-33, F(1, 38) = 2.19, p = .15, η2 = .06 (Figure 4).  
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Following this, to test whether women’s history of CA moderated the relation 
between participants’ history of rMDD and stimulated cytokine levels, we ran a series of 
ANOVAs using immune reactivity for each of the cytokines (IL-1β, IL-6, IL-10, and IL-
33) as a dependent variable and rMDD, CA, and the rMDD × CA interaction as 
independent factors. We found no significant main effect of CA history on stimulated 
levels of IL-1β, F(1, 38) = 0.54, p = .47, η2 = .02, IL-6, F(1, 38) = 1.34, p = .25, η2 = .04, 
IL-10, F(1, 38) = 0.03, p = .86, η2 = .001, or IL-33, F(1, 38) = 0.002, p = .96, η2 < .001.  
In addition, the rMDD × CA interaction was not significant for any of the cytokines: IL-
1β, F(1, 38) = 0.15, p = .70, η2 = .004, IL-6, F(1, 38) = 0.90, p = .35, η2 = .02, IL-10, F(1, 
38) = 0.50, p = .48, η2 = .01, or IL-33, F(1, 38) = 1.23, p = .27, η2 = .03. Again, the 
results remained unchanged, when we excluded participants with a current MDD 
diagnosis (n = 2), men (n = 5), or both (n = 6). Please see Study 1 supplementary data 
section for detail. 
Exploratory analyses. To examine whether levels of anhedonia, assessed using 
MASQ –AD subscale, were associated with increased circulating levels of cytokines, we 
conducted exploratory correlations analyses using all circulating (n = 4; IL-6, IL-10, IL-
33, and TNFα) and stimulated (n = 14; IL-1β, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, 
IL-23, IL-25, IL31, IL-33,TNFα, IFNγ, and sCDL40) cytokines for which the data was 
available in the multiplex array. There was no significant association between current 
anhedonia and circulating levels of IL-6, r(37) = –.11, p = .51, IL-10, r(37) = –.01, p = 
.96, or IL-33, r(37) = –.13, p = .45.  
To examine whether levels of anhedonia were associated with increased 
stimulated levels of cytokines, we conducted similar analyses. We found that higher 
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levels of anhedonia symptoms were associated with increased stimulated levels of IL-33, 
r(37) = .46, p = .006 (Figure 5), but not IL-1β, r(37) = .17, p = .31,  IL-6, r(37) = .14, p = 
.38, or IL-10, r(37) = .23, p = .15. Notably, the association between anhedonia and 
stimulated levels of IL-33 was maintained when we statistically controlled for 
participants’ age, r(36) = 0.40, p = .38, sex, r(36) = 0.44, p = .006, ethnicity (Caucasians 
vs. others), r(39) = 0.45, p = 0.005, income, r(36) = 0.45, p = .01, body mass index 
(BMI), r(36) = 0.45, p = .005,  body temperature, r(36) = 0.44, p = .006, time of sample 
collection r(36) = 0.46, p = .004, or lifetime smoking, r(36) = 0.41, p = .01.  
We conducted similar analysis to examine the association between current 
anhedonia symptoms and stimulated cytokine levels among individuals with no current 
MDD diagnosis (n = 37). The results remained unchanged and we found that higher 
levels of anhedonia symptoms were associated with increased stimulated levels of IL-33, 
r(35) = .38, p = .02, but not IL-1β, r(35) = .11, p = .53,  IL-6, r(35) = .09, p = .59, or IL-
10, r(35) = .22, p = .19. The results were maintained when we conducted similar analyses 
among women only (n = 34): IL-33, r(33) = .47, p = .005, IL-1β, r(33) = .21, p = .24,  IL-
6, r(33) = .21, p = .23, and IL-10, r(33) = .27, p = .13. Lastly, the results were also 
maintained when we excluded both individuals with a current MDD diagnosis and men 
(n = 33): IL-33, r(32) = .42, p = .01, IL-1β, r(32) = .13, p = .48,  IL-6, r(32) = .14, p = 
.45, or IL-10, r(32) = .26, p = .14.  Intriguingly, exploratory analyses showed significant 
association between anhedonia symptoms and other cytokines, including IL-17A, IL-17F, 
IL-21, IL-22, IL-23, IL-31, IFNγ, and sCDL40. Full results can be found in the Study 1 
supplementary data section.  
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Additionally, to examine whether the association between anhedonia symptoms 
and stimulated cytokine levels were moderated by participants’ history of rMDD, we 
conducted a series of ANOVAs using stimulated cytokine levels as a dependent variable, 
and rMDD history, anhedonia symptoms, and their interaction as independent variable. 
We found a significant main effect of rMDD history on stimulated levels of IL-1β, F(1, 
38) = 8.99, p = .005, η2 = .20, and a significant rMDD × anhedonia interaction,  F(1, 38) 
= 8.75, p = .006, η2 = .20, but no significant main effect of anhedonia on stimulated levels 
of IL-1β, F(1, 38) = 1.79, p = .19, η2 = .05.  To examine the form of this interaction, we 
ran correlation analysis separately among individuals with and without rMDD history. 
We found that anhedonia was significantly associated with stimulated IL-1β levels 
among individuals with rMDD history, r(18) = .54, p = .02,  but not among individuals 
with no rMDD history, r(17) = –.31, p = .20.  
Similarly, for stimulated IL-6 levels, we found a significant main effect of rMDD 
history, F(1, 38) = 8.02, p = .008, η2 = .19,  and a significant rMDD × anhedonia 
interaction,  F(1, 38) = 7.73, p = .009, η2 = .18, but no significant main effect of 
anhedonia on stimulated levels of IL-1β, F(1, 38) = 1.43, p = .24, η2 = .04. As before, we 
ran correlation analysis separately among individuals with and without rMDD history.  
We found that anhedonia was significantly associated with stimulated IL-6 levels among 
individuals with rMDD history, r(18) = .58, p = .007,  but not among individuals with no 
rMDD history, r(17) = –.25, p = .31.  
For stimulated levels of we found no significant main effect of rMDD history, 
F(1, 38) = 0.001, p = .98, η2 <.001,  anhedonia, F(1, 38) = 1.27, p = .27, η2 = .04, or 
rMDD × anhedonia interaction,  F(1, 38) <0.001, p = 1.00, η2 < .001. 
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Lastly, for IL-33, we found a significant main effect of anhedonia, F(1, 38) = 
6.35, p = .02, η2 = .15, but not rMDD history, F(1, 38) = 1.91, p = .18, η2 = .05, or rMDD 
× anhedonia interaction,  F(1, 38) = 2.03, p = .16, η2 = .06. 
In summary, the results of this first study provided no support for the association 
between participants’ history of rMDD and circulating or stimulated levels of IL-1β, IL-
6, IL-10, or IL-33. Additionally, there was no evidence supporting the hypothesis that a 
history of CA would moderate the relation between rMDD and circulating or stimulated 
levels of IL-1β, IL-6, IL-10, or IL-33. However, the results of exploratory analyses 
suggest a link between participants’ current levels of anhedonia and stimulated, but not 
circulating, levels of IL-33, and other T-helper 17 cytokines that were included in the 
array, such as IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-31, IFNγ, and sCDL40, 
highlighting the association between stimulated, but not circulating cytokine levels and 
anhedonia symptoms. Intriguingly, rMDD moderated the association between anhedonia 
and stimulated IL-1β and IL-6 levels, such that greater levels of anhedonia were 
associated with higher stimulated IL-1β and IL-6 levels only among individuals with a 
history of rMDD. 
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Study 2 
Building on the reported association between inflammation and anhedonia 
symptoms in humans, Study 2 focused on investigating the influence of adolescent stress 
exposure on anhedonia-like behavior in response to an in-vivo immune challenge in adult 
rats. Additionally, we aimed to test whether different type of stressors could affect the 
magnitude of the behavioral response to an immune challenge in adulthood and employed 
chronic escalating stress (CES) and acute stress paradigms (AFS). We hypothesized that 
animals exposed to adolescent stressors receive would exhibit greater levels of 
anhedonia, assessed via sucrose preference test, following an LPS challenge in adulthood 
compared to animals with no history of adolescent stress exposure or vehicle-injected 
animals.  
Method 
Subjects and Procedure. Figure 6 illustrates the timeline of the present study. 
Specifically, 32 female Sprague–Dawley rats, which were bred on site using pathogen-
free breeders originally derived from Harlan (Envigo), were randomly assigned to one of 
four conditions: (i) chronic escalating stress (CES) + adult LPS challenge, (ii) acute 
footshock only (AFS) + adult LPS challenge, (iii) no adolescent stress + adult LPS 
challenge, and (iv) no adolescent stress or adult LPS challenge. Rats were allowed to
 develop normally until P21, at which point animals were weaned and housed 
with age and sex-matched partners (non litter-mates), 2 per cage, under standard 
conditions. Following a 6-day acclimation to colony conditions (P27), rats were handled 
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by researchers for 2–3 min to familiarize them with human contact prior to 
experimentation. Rats in the CES condition went through the adolescent stress challenge 
procedure described in detail below from P28-P39, whereas animals in the AFS condition 
were stressed for one day only (P39). Animals were treated in accordance with Public 
Health Service (PHS) policy and all experimental protocols were approved by the 
Institutional Animal Care and Use Committee (IACUC) at Binghamton University. 
Adolescent stress paradigm.  These studies used a novel model of Chronic 
Escalating Distress involving an 11-day procedure culminating in footshock exposure on 
the last day, which has recently been shown to produce robust neuroimmune changes and 
altered alcohol sensitivity (Doremus-Fitzwater et al., 2018). Rats assigned to the 
escalating chronic stress paradigm were first subjected to 5 days of whole body restraint 
lasting 60 minutes (P28). Starting at P33, the 60-minutes of restraint was preceded by a 
30-minute forced swim each day for 5 days. Finally, on P39, rats were subjected a 120-
minute foot shock. The footshock chamber measured 30.5 (L) × 26.5 (W) × 33 (H) cm 
(Habitest Chamber, Model H10-11R-TC-SF, Coulbourn Instruments, Allentown, PA). 
The sidewalls of the chamber were constructed of stainless steel except the front doors 
that were constructed of clear Plexiglas. The chambers were adapted to deliver scrambled 
shocks through the grid floor (18 bars spaced 1.1 cm apart with a diameter of 4.0 mm) 
from a shock generator (LABLINC Model H01-01, and Precision Animal Shocker Model 
H13-15, Coulbourn Instruments, Allentown, PA). The sound-attenuating chambers were 
illuminated by a 20-W white light bulb and background noise was provided by individual 
ventilation fans. Animals were exposed to inescapable footshocks (1.0 mA, 5 s each, 90 s 
variable intertribal interval [ITI]) for 120 min (approximately 80 shocks). Timeline for 
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this CES procedure is depicted in  6. Animals in the AFS condition remained undisturbed 
in their home cages from P28 until P39, when they were subjected to the footshock 
procedure, identical to that in the CES condition. 
In vivo LPS challenge. Rats remained undisturbed in their home cages until P70, 
at which point all animals (n = 24) except those in the no adolescent stress/no adult LPS 
challenge condition were administered an intraperitoneal (i.p.) injection of LPS.  The 
LPS (L6529, Sigma- Aldrich, St. Louis, MO) solution was diluted to 1.0 mg/mL using 
sterile endotoxin-free isotonic saline and stored in frozen aliquots at −20°C until use. On 
the day of experimentation, an aliquot of LPS was thawed and mixed fresh daily to the 
working concentration of 100 μg/mL LPS and delivered on a 1 mL/kg basis, also in 
pyrogen-free physiological saline. The dose of LPS was selected on the basis of its 
reported ability to induce depression-like behaviors in rats (Bison et al., 2009). 
Immediately following injection of LPS, the animals were returned to their home cages 
where they remained undisturbed for 0.5h. The rest of the animals were administered (n = 
8) sterile endotoxin-free isotonic saline. 
Sucrose preference time course. Given that sucrose is a palatable solution for 
rats, its decreased consumption was used as an index of anhedonic symptoms. Initially, 
all animals were granted free access to a 1% sucrose solution, in addition to regular food 
and water, for 4 days for habituation (P66-P70; Bison et al., 2009). On P70, all animals 
were presented with water and a 1% sucrose solution in graduated bottles with fitted 
sipper-tubes in their home cages, in addition to regular food.  Specifically, Plexiglas 
dividers were installed in each cage to separate animals and ensure that each animal has 
access to their own bottles of sucrose solution and water. Total cumulative fluid 
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consumption (mL) defined as the sum of water and sucrose solution intake, was assessed 
30 minutes, 1h, 2h, 4h, 8, and 16h later. The timing was chosen based on previous 
research (Bison et al., 2009). A sucrose solution preference score was calculated as the 
percentage of sucrose solution intake (%= sucrose solution intake × 100/total fluid 
consumption).  
Results  
First, to examine the potential effect of group on rats’ body weight, we ran an 
ANOVA using weight as a dependent variable and group as an independent factor. We 
found no significant effect of group on animals weight at P66, which was the beginning 
of sucrose habituation procedure, F(3,31) = .24, p = .87, η2 = .02. To examine the effect 
of adolescent stress exposure on anhedonia-like behavior (sucrose preference) in 
adulthood, we conducted a 4 (Group: AFS+LPS, CES+LPS, NS+LPS, and NS+Veh) × 6 
(Time: 0.5, 1, 2, 4, 8, and 16h) repeated measures ANOVA with sucrose preference 
serving as the dependent variable. Sucrose preference was calculated using sucrose and 
water consumption data normalized by individual animal’s weight. The values were then 
winsorized to normalize their distribution. We found a significant main effect of time on 
animal’s sucrose preference, F(5,135) = 4.41, p = .001, η2 = .14, with animals generally 
exhibiting a linear increase in sucrose preference over time. The main effect of group on 
sucrose preference was a nonsignificant trend, F(5,135) = 2.36, p = .09, η2 = .21, and the 
group × time interaction was nonsignificant,  F(5,135) = 1.13, p = .33, η2 = .11 (Figure 
8). Sucrose and water consumption analyses and time course during the sucrose 
preference test can be found in the supplementary section (Supplementary Figure 1). 
There was no support for the effect of adolescent stress exposure and in-vivo immune 
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challenge in adulthood on adult levels of anhedonia-like behavior in rats. However, the 
marginally significant trend found in this study suggests that conducting similar studies 
using fewer stress conditions and/or increased group sample sizes is warranted. 
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Study 3 
 Whereas Study 2 examined the potential impact of early life stress on the 
behavioral response to an immune challenge in adulthood, the current study focused on 
the impact of early life stress on the neurobiological processes potentially underlying that 
behavioral response. Translational studies as such frequently use animals injected with 
the cytokine inducer LPS (Kujawa et al., 2015) and describe an LPS-stimulated increase 
in cytokine gene expression (Erickson & Banks, 2011; Rey, Randolf, Wildmann, 
Besedovsky, & Jessop, 2009). Given that inflammation may be linked to increased levels 
of psychopathology in many, but not all individuals (Slavich & Irwin, 2014), 
identification of factors that may potentiate immune responses and specific biological 
processes underlying this process is critical for improving prevention effort and 
developing targeted interventions. Exposure to early life stress is emerging as one such 
factor in a rapidly growing body of literature (Muscatell, Slavich, Monroe, & Gotlib, 
2009; Slavich & Irwin, 2014). For example, a stressful early life environment has been 
associated with increased immune reactivity in adolescence (Miller & Chen, 2010). 
Additionally, findings from a prospective study suggest that cumulative stress exposure 
in childhood was related to greater circulating levels of inflammation in adolescence 
(Slopen, Kubzansky, McLaughlin, & Koenen, 2013). Findings from animal translational 
research are similar and suggest that adolescent stress exposure may magnify peripheral 
immune response to a predatory stressor in adulthood (Barnum, Pace, Hu, Neigh, & 
Tansey, 2012). What remains unclear is whether adolescent stress exposure leads to a 
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potentiated neuroimmune response specifically to immune challenges in adulthood in the 
brain areas related to reward processing and stress and whether this sensitization was 
related to a specific type of stressors. Therefore, Study 3 focused on examining the 
influence of adolescent stress exposure on cytokine gene expression in brain regions 
associated with reward and emotion processing in response to an in vivo LPS challenge in 
adult rats. Additionally, to examine the potential effect of different stressor 
characteristics, including length and stressor variability, we employed two types of 
stressors: Chronic Escalating Stress (CES) and Acute Footshock (AFS) that were used in 
Study 2. We hypothesized that animals in the CES and AFS groups would evidence the 
greatest expression of inflammatory genes (IL-1β, IL-6, IL-10, IL- 33) in the VTA, AMG, 
NAc, and PVN in response to an LPS challenge in adulthood, compared to rats that had 
no exposure to an adolescent stressor. 
Method 
Subjects and Procedure. The subjects and procedure were similar to those used in Study 
2 (Figure 9). Briefly, 32 female Sprague–Dawley rats, bred on site using pathogen-free 
breeders were randomly assigned to one of the four conditions: CES +LPS, AFS+LPS, 
NS+LPS, and NS+Veh. Rats were allowed to develop normally until P21, at which point 
animals were weaned and housed with age and sex-matched partners (non litter-mates) 
under standard conditions. Rats were handled by researchers (P27) for 2–3 min to 
familiarize them with human contact prior to experimentation. Rats in the CES went 
through the adolescent stress challenge procedure described in detail below from P28-
P39, whereas animals in the AFS condition were stressed on one day only (P39). Animals 
were treated in accordance with Public Health Service (PHS) policy and all experimental 
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protocols were approved by the Institutional Animal Care and Use Committee (IACUC) 
at Binghamton University. 
Adolescent stress paradigm.  The procedure was identical to that used in Study 
2. Briefly, rats that were assigned to the escalating chronic stress paradigm were first 
subjected to 5 days of whole body restraint lasting 60 minutes (P28). At P33, 60-minute 
restrain was preceded by a 30-minute forced swim for 5 days. On P39 rats were exposed 
to inescapable footshocks for 120 min (approximately 80 shocks). Timeline for this CES 
procedure is depicted in Figure 7. Animals in the AFS condition remained undisturbed in 
their home cages from P28 until P39, when they were subjected to the footshock 
procedure, identical to that in the CES condition. 
In vivo LPS challenge.  This procedure was also identical to that described in 
Study 2. Specifically, on P70, all animals (n = 24) except for those in the NS + Veh 
condition were administered an i.p. injection of 100 μg/mL LPS and delivered on a 1 
mL/kg basis in pyrogen-free physiological saline.  Immediately following injection of 
LPS, the animals were returned to their home cages where they remained undisturbed for 
1h. 
Cytokine gene expression. All RT-PCR was conducted using previously 
described procedures (Hueston & Deak, 2014). Rats were sacrificed via rapid 
decapitation (unanesthesized) 1h following LPS/Saline injections. Brains were removed 
and stored at −80°C. The VTA, AMG, NAc, and PVN  were identified using a rat brain 
atlas (Watson & Paxinos, 2005), punched using biopsy punches, and stored at –80 °C 
until the time of RNA extraction. Tissue samples were homogenized in Trizol RNA 
reagent (Invitrogen) using a TissueLyser and 5 mm stainless steel beads (Qiagen, 
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Germantown, MD). Total RNA was then extracted via RNeasy mini columns (Qiagen, 
Germantown, MD) following manufacturer’s instructions. RNA yield and purity were 
evaluated using a Nanodrop system (Thermo Fisher Scientific, Waltham, MA) and cDNA 
was synthesized using a QuantiTect reverse transcription kit (Qiagen, Germantown, MD). 
All RT-PCR was run using a CFX384 real-time PCR detection system (Bio-Rad, 
Philadelphia, PA).  Relative gene expression was quantified using the 2- ΔΔCT method. 
Primer sequences for all targets run can be found in Table 2. Results were normalized to 
GAPDH as a housekeeper gene. Significant group differences in GAPDH expression 
were observed in the AMG, F(3,31) = 3.14, p = .04, η2 = .25 (Supplementary Figure 2). 
Thus, non-normalized data was used in all analyses of cytokine gene expression for that 
region. There were no significant group differences in GAPDH expression in any of the 
other brain regions (lowest p = .27). Values > 2 SDs away from the mean were classified 
as outliers and excluded from the analysis. Two outliers identified in the expression of 
GAPDH in the NAc also produced extreme values in the expression of several cytokines 
in other regions and were therefore excluded from all subsequent analyses.  
Results 
To test the hypotheses from Study 3, we conducted a series of 4 (region: NAc, 
VTA, AMG, and PVN) × 4 (group: CES+LPS, AFS+LPS, NS+LPS, and NS+Veh) 
repeated measures ANOVAs separately for IL-1β, IL-6, IL-10, and IL-33.  For IL-1β, we 
found a significant main effect of region, F(3,78) = 3.48, p = .02, η2 = .12, but no 
significant effect of group, F(3, 26) = 1.19, p = .33, η2 = .12, or group × region 
interaction, F(9,78) = 1.18, p = .32, η2 = .12. Post hoc analysis revealed that IL-1β 
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expression was significantly higher in the NAc compared to the VTA, p = .02, and AMG, 
p < .001, with no differences between any other groups (lowest p = .08).  
For IL-6, we found a significant main effect of region, F(3,66) = 4.64, p = .005, η2 
= .17, but no significant effect of group, F(3, 26) = 0.90, p = .46, η2 = .11, or region or 
group × region integration, F(9,66) = 0.72, p = .69, η2 = .09. Post hoc analysis revealed 
that IL-6 expression was significantly lower in the NAc compared to the VTA, p = .05, 
and PVN, p = .004, with no differences between any other groups (lowest p = .08).  
For IL-10, we found a significant main effect of region, F(3,72) = 3.39, p = .02, η2 
= .12, but no significant effect of group, F(3, 24) = 1.06, p = .40, η2 = .12, or region or 
group × region integration, F(9,66) = 0.72, p = .69, η2 = .09. Post hoc analysis revealed 
that IL-10 expression was significantly lower in the AMG compared to the NAc, p = .03, 
VTA, p = .01, and PVN, p = .02, with no differences between any other groups (lowest p 
= .38).  
For IL-33, we found a significant main effect of region, F(3,78) = 3.27, p = .03, η2 
= .11, but no significant effect of group, F(3, 26) = 0.36, p = .78, η2 = .04, or region or 
group × region integration, F(9,78) = 1.09, p = .38, η2 = .11. Post hoc analysis revealed 
that IL-33 expression was significantly lower in the AMG compared to the NAc, p = 
.009, VTA, p = .004, and PVN, p = .03, with no differences between any other groups 
(lowest p = .31). The results are depicted in Figure 10. 
We found no support for differences in the expression of IL-1β, IL-6, IL-10, or IL-
33 in the brain areas associated with reward processing and stress based on animal’s 
history of early life stress. Lack of a significant increase in the cytokine expression 
among animals who had no stress exposure in adolescence but went through an immune 
  37 
challenge in adulthood suggests that the timing between the LPS injection and tissue 
collection might have been insufficient for an expected neuroinflammatory response to 
develop. 
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Discussion 
The current investigation aimed to answer a line of research questions related to 
the role of stress and inflammation in depression and anhedonia. The project consisted of 
a series of complimentary human and animal studies and integrated multiple modes of 
assessment (circulating levels, cytokine reactivity, gene expression) to examine the 
following research areas: (1) the link between history of recurrent major depressive 
disorder (rMDD) and inflammatory markers and how this may be moderated by history 
of childhood abuse in women, (2) the association between inflammatory markers and 
current anhedonia symptoms in the same sample of women, (3) the effect of early life 
stress on anhedonia-like behavior in adult rats, and (4) effect of early life stress on 
inflammatory gene expression in brain areas related to stress and reward processing in 
adult rats. The use of both human and animal research methodologies allowed us to 
extend the scope of our investigation from using in vitro techniques in humans to in-vivo 
immune challenge in rats to examining the causal effects of early life stress on immune 
responses, as well as to expand the investigation from peripheral markers of 
inflammation in humans to potential brain mechanisms in rats. 
Specifically, Study 1 examined whether a history of rMDD was associated with 
greater circulating and stimulated levels of inflammatory markers (IL-1β, IL-6, IL-10, or 
IL-33) in adult women and whether this relation was moderated by their history of 
childhood abuse. Additionally, this study examined the association between stimulated 
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levels of inflammatory markers and current symptoms of anhedonia. We found no 
support for the first two aims and some support for the latter one. Specifically, 
participants’ history of rMDD was not related to either circulating or stimulated levels of 
any of the cytokines examined, which contradicts our hypothesis of increased 
inflammation being a trait-like marker of depression, independent of current depression. 
Furthermore, women’s retrospectively reported history of childhood abuse did not 
moderate the link between rMDD and circulating or stimulated cytokine levels, which is 
inconsistent with previous research (Danese et al., 2008). One difference between the two 
studies is that Danese et al. (2008) examined the moderating effect of early life stress 
among individuals with a current depression diagnosis, whereas we investigated those 
with a history of MDD, which could have impact the results. Therefore, future research 
could concentrate on the moderating role of childhood abuse in the context of 
inflammation during a current depressive episode. Another limitation of this study, 
particularly for the moderation analyses, is the sample size and future research using 
more participants is needed. We should also note that, in the current study, women with a 
history of childhood abuse evidenced higher circulating levels of IL-6 than women with 
no history of childhood abuse. This is consistent with previous meta-analysis showing 
that history of childhood trauma was associated with greater circulating levels of 
inflammatory markers, including IL-6 (Baumeister, Akhtar, Ciufolini, Pariante, & 
Mondelli, 2016). 
As noted above, a secondary aim of Study 1 was to examine the association 
between anhedonia and inflamamtion. Although levels of anhedonia were not 
significantly related to circulating levels of any of the cytokines examined, we found that 
  40 
higher stimulated levels of IL-33 and eight other Th17 cytokines produced by monocytes 
and macrophages (IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IFNγ, and 
sCDL40) were associated with higher levels of anhedonia in women, suggesting the 
potential involvement of inflammatory processes in anhedonia, a key symptom of 
depression.  Moreover, we found that participants’ history of rMDD moderated the 
association between current anhedonia and induced levels of IL-1β and IL-6, such that 
greater levels of anhedonia were associated with greater levels of IL-1β and IL-6 only 
among participants who also had a history of rMDD. This is consistent with a growing 
body of research focusing on the role of inflammation in anhedonia. Despite the growing 
recognition of the need to study dimensional constructs underlying core features of 
psychopathology, including MDD, in addition to focusing on specific diagnoses (Carcone 
& Ruocco, 2017; Zalta & Shankman, 2016), research examining depression beyond 
vegetative and somatic manifestations of depression is scarce (Slavich & Irwin, 2014). 
However, this growing body of literature highlights the role of inflammation in 
anhedonia. For example, increased circulating levels of CRP, IL-1β, IL-1RA, and IL-6 
were found to be associated with decreased connectivity in corticostriatal reward and 
motor neurocircuitry (Felger et al., 2015) underlying anhedonia symptoms (Heshmati & 
Russo, 2015).  Moreover, previous research points out that as a trans-diagnostic symptom 
of many psychiatric and medical conditions, anhedonia may be impacted by common 
immune mechanisms that impact reward processing, including TH-17 mediated immunity 
(Contreras et al., 2016; Escalona & Fawcett, 2017; Swardfager, Rosenblat, Benlamri, & 
McIntyre, 2016). The current findings, therefore, provide promising evidence that 
supports and extends this research to stimulated, but not circulating levels of cytokines 
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and points to new targets among inflammatory markers. However, because the analyses 
of those cytokines were exploratory, conclusions must remain tentative pending 
replication. This said, the results do suggest the utility of exploring the role of more novel 
inflammatory markers beyond those most commonly researched in this context and 
testing the moderating role of rMDD.  
The main aim of Study 2 was to examine the role of adolescent stress exposure on 
behavioral response to an immune challenge in adult rats. We were particularly interested 
in anhedonia-like behavior and employed a well-established sucrose preference paradigm 
that is commonly used to index anhedonia in rodents (Der-Avakian & Markou, 2012). 
We also compared two different types of stressors, chronic escalating stress (CES) and 
acute footshock (AFS) to examine the potential effects of stressor characteristics. In 
addition, rather than only examining the effect of an immune challenge on anhedonia 
during a single time point, we assessed sucrose preference at 6 different timepoints: 0.5, 
1, 2, 4, 8, and 16 hours following systemic LPS administration. We found a marginally 
significant trend for stress condition differences in sucrose preference. Specifically, rats 
in the AFS group generally evidenced decreased preference for sucrose compared to 
animals that were not exposed to stress as adolescents (whether they received a vehicle 
injection or LPS challenge in adulthood). This trend is consistent with previous research 
suggesting that an exposure to a severe stressor (24-h restraint) may induce a lasting 
depression-like phenotype, including decreased glucose uptake in the brain and 
hippocampal neurogenesis in mice (Chu et al., 2016). When sucrose consumption vs. 
preference was examined, there was a significant time × group interaction, such that 
animals that were not subjected to adolescent stress and were administered saline instead 
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of LPS in adulthood (NS+Veh) evidenced significantly higher sucrose consumption 
compared to rats in all other groups (NS+LPS, CES+LPS, and AFS+LPS) 8 hours 
following the immune challenge. There are several possible reasons why marginally 
significant vs. significant results were obtained with sucrose preference including lack of 
power to detect significant differences in animal behavior. Indeed, this study evidenced 
an effect size that was medium in magnitude (η2 = .21), supporting the effect of group 
assignment on sucrose preference and encouraging of future research using larger sample 
sizes. A second potential reason for our overall lack of significant results may have been 
due to the developmental timing of the stressor. Our timing (P28) allowed us to avoid the 
stress hyporesponsivity phase described by previous research, during which animals 
evidence blunted corticosteroid response to stressors (Levine, 2001). Although no  
studies, of which we know, compared the long-term impact of post-natal vs. adolescent 
stress on adult functioning, there is evidence that adolescent rats display severely blunted 
neuroimmune responses, compared to adult animals (Doremus-Fitzwater, Gano, Paniccia, 
& Deak, 2015). Thus, future research may consider this aspect when studying the effect 
of early life stress on behavioral responses to an immune challenge in adult rodents. 
 Building from the previous two studies, Study 3 focused on the role of early life 
stress in neuroinflammatory response to an immune challenge later on in life. 
Specifically, the main aim of Study 3 was to examine the effect of adolescence stress 
exposure on inflammatory gene expression in brain areas underlying reward processes 
and stress, including the nucleus accumbens (NAc), ventral-tegmental area (VTA), 
amygdala (AMG), and paraventricular nucleus of the hypothalamus (PVN). Similar to 
Study 2, we used two types of adolescent stress, CES and AFS, and an identical 
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procedure for the immune challenge in adulthood. We found no significant group 
differences in IL-1β, IL-6, IL-10, or IL-33 gene expression in any of the brain areas we 
examined. The reason for this may lie in an insufficient time (1h) between an LPS 
administration and tissue collection. Specifically, we did not observe the expected 
increase in inflammatory markers among animals who were not exposes to an adolescent 
stressor but were administered LPS as adults, suggesting that the brain samples were 
collected before the immune response fully unfolded. For example, LPS in-vivo challenge 
has been shown to increase IL-1β and IL-6 expression in the PVN and AMG of adult rats 
3 hours following the injection (Doremus-Fitzwater et al., 2015). Moreover, a study that 
examined a range of LPS doses (1, 5, 15, 50, 125, and 250 μg/kg) reported an increase in 
circulating IL-1β, IL-6, IL-10 levels 2 hours post injection starting at 5 μg/kg (Bison et 
al., 2009). In a separate study that used a much higher dose of LPS (2mg/kg), levels of 
circulating inflammatory markers (IL-1β) increased 30 minutes following an injection, 
while IL-1β hippocampal gene expression significantly increased 24h following an 
immune challenge and peaked at day 7 (Fu et al., 2014). Future research examining the 
time course for the LPS-induced neuroinflammation in the brain areas related to 
anhedonia is needed to inform studies in this area.  
The primary strength of this study was the integration of human and animal 
methodologies that allowed us to examine a range of research questions related to the 
interplay between stress, inflammation, and depression.  Additional strengths included (i) 
the use of structured clinical interviews to obtain women’s diagnostic histories in Study 
1, (ii) the focus on both circulating and stimulated levels of inflammatory markers in 
Study 1, (iii) the assessment of change in anhedonia-like behavior over time, as opposed 
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to only a single assessment, in Study 2, and (iv) the focus on cytokine gene expression in 
several specific brain regions related to anhedonia in Srudy 3. Despite these strengths, 
there are limitations that provide directions for future research. For example, the cross-
sectional design of Study 1 precludes us from making any causal conclusions and future 
research utilizing prospective design is needed to determine whether higher levels of 
immune reactivity are a cause, consequence, or only a correlate of anhedonia symptoms. 
Additionally, estrous phase was not monitored in Studies 2 and 3, which may have 
impacted the results. Estrous cycle is known to affect animal behaviors, including food 
intake (Asarian & Geary, 2006) as well as inflammatory response to stress (Arakawa, 
Arakawa, Hueston, & Deak, 2014). Therefore, including estrous cycle data is 
recommended for future research using female rodents. Additionally, we did not assess 
for where women were in their menstrual cycle, which has been shown to affect 
peripheral inflammation levels (Bertone-Johnson et al., 2014) and, therefore, could have 
impacted the results. Moreover, no information about participant’s habitual dietary intake 
or exercise was collected. Given that previous research describes the impact of dietary 
composition (Galland, 2010) and exercise routine (Kelley & Kelley, 2006) on systemic 
inflammatory markers, future studies that include these data in the analyses are 
warranted. 
In summary, this investigation found no support for our hypotheses regarding the 
association between a history of rMDD and circulating or stimulated levels of cytokines, 
which may be due to study limitations or lack of a robust relation between inflammation 
and history of depression, which could be more evident among currently depressed 
individuals. Additionally, we found no support for the moderation of this association by a 
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history of early life stress. There was a significant relation between a history of childhood 
abuse and circulating levels of IL-6, which is consistent with previous research 
highlighting the link between early life-stress and inflammation in adulthood, 
corroborating existing evidence for the lasting effects of early life stress on immune 
processes. Additionally, there was evidence of an association between stimulated levels 
of inflammatory markers and current symptoms of anhedonia, which was maintained 
when we statistically controlled for potential confounders, including relevant 
demographic and physiological variables. This finding is in line with a small, but 
growing body of literature supporting the role of inflammation in anhedonia and extends 
previous research by showing the link between levels of cytokines released in response to 
an in vitro immune challenge with a known endotoxin and andhedonia. Pending 
replication and longitudinal research, these findings could lead to more detailed 
understanding of this trans –diagnostic phenomenon and inform treatment development. 
We extended this line of research questions to examining the causal relationship between 
early life stress and the andhedonia in adulthood following an in-vivo immune challenge 
using an animal sample. We found a marginally significant trend for the effect of early 
life stress on increased in andhedonia-like behavior in rats following an immune 
challenge with a known endotoxin. Additionally, we expanded the scope of our 
investigation to examining the effect of early life stress on neuroinflammation in the 
brain areas underlying stress and anhedonia processes following an immune challenge in 
adulthood. We found no support for increased expression of inflammatory genes in those 
areas following an immune induction in adulthood among animals that were stressed as 
adolescents. This investigation demonstrates the value of cross-species interdisciplinary 
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design in psychopathology research that is currently underutilized, yet much needed in 
the field. Indeed, researchers in our field commented on how psychological science is 
uniquely positioned due to its natural overlap with many other disciplines, to benefit from 
the interdisciplinary effort (Cacioppo, 2007). Additionally, pending future replication, the 
findings related to the association of current anhedonia symptoms and anhedonia-like 
behavior highlight the emerging research initiative to focus on processes that manifest in 
various forms of psychopathology, rather than solely diagnosis-based design.  
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Table 1. Descriptive statistics for participants in Study 1 
   
No rMDD History 
 
History of rMDD 
 
 
 reffect size 
(n = 19)  (n = 20) 
 
    
Parent Age (M, SD) 38.68 (8.29) 35.03 (6.47) – .25 
    
Parent Ethnicity                    
(% Caucasian) 
78.9 73.7 – .01 
    
Sex (% female) 89.5 85.0 – .01 
    
Annual Family Income 45,001-50,000 25,001-30,000 – .26 
    
BDI-II (M, SD) 5.71(6.83) 10.43 (9.50)    .66** 
    
MASQ AD (M, SD) 52.83 (13.17) 68.81 (12.38)    .54** 
    
CTQ (% with a history of 
moderate or severe abuse) 
36.8 65.0    .28 
    
BMI (M, SD) 31.88 (5.12) 36.10 (8.58)    .29 
    
Body Temperature (M, SD) 98.22 (.59) 98.20 (.56) – .02 
    
Lifetime cigarette smoking 
(% who smoked >100) 
42.1  57.9      .28 
    
Note. BDI-II = Beck Depression Inventory-II, rMDD = Recurrent Major Depressive 
Disorder, MASQ AD = Mood and Anxiety Symptom Questionnaire- Anhedonia 
subscale, MASQ AA = Mood and Anxiety Symptom Questionnaire- Anxious Arousal 
subscale, BMI = Body Mass Index  
*p < .05. **p < .01 
  
  48 
Table 2. Primer sequences used in Study 3. 
    
Name: Sequence: 
  
GAPDH Forward 5' GTG CCA GCC TCG TCT CAT AG 3' 
  
GAPDH Reverse 5' AGA GAA GGC AGC CCT GGT AA 3' 
  
IL-1β Forward 5' CAG CTT TCG ACA GTG AGG AGA 3' 
  
IL-1β Reverse 5' TGT CGA GAT GCT GCT GCT GTG AG 3' 
  
IL-6 Forward 5' TAG TCC TTC CTA CCC CAA CTT CC 3' 
  
IL-6 Reverse 5' TTG GTC CTT AGC CAC TCC TTC 3' 
  
IL-10 Forward 5' TGC GAC GCT GTC ATC GAT TT 3' 
  
IL-10 Reverse 5' TGG CCT TGT AGA CAC CTT TGT 3' 
  
IL-33 Forward 5' CCT GAG CAC ATA CAA CGA CCA 3' 
  
IL-33 Reverse 5' TTC TTC CCA TCC ACA CCG TC 3' 
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Figure 1. Schematic of the parallels between human and animal research questions in this 
project. In vitro and in-vivo challenges = Lipopolysaccharide (LPS) treatment/injections. 
Combining human and animal research allowed us to parallel an in vitro immune 
challenge in humans with an in-vivo challenge in rats and extend the scope of our 
investigation from assessing PBMC cytokine production to mRNA levels in the bran 
regions of interest.   
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Figure 2. Differences in circulating levels of cytokines based on participants’ history of 
rMDD. No significant differences in circulating levels of IL-6 (A), IL-10 (B) or IL-33 (C) 
were detected based on participants’ history of rMDD. Bars represent the mean and 
standard error of the mean (SEM). 
  
rMDD History No rMDD History
0.00
0.05
0.10
0.15
C
irc
ul
at
in
g 
Le
ve
ls
 o
f I
L-
6 
(lo
g)
A
rMDD History No rMDD History
0.0
0.5
1.0
1.5
C
irc
ul
at
in
g 
Le
ve
ls
 o
f I
L-
33
 (l
og
)
C
rMDD History No rMDD History
0.00
0.05
0.10
0.15
C
irc
ul
at
in
g 
Le
ve
ls
 o
f I
L-
10
 (l
og
)B
  51 
 
 
 
Figure 3. Differences in stimulated levels of IL-6 based on participants’ history of CA. 
Parcipants with a history of CA evidenced higher stimulated levels of IL-6. Bars 
represent the mean and standard error of the mean (SEM). 
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Figure 4. Differences in stimulated levels of cytokines based on participants’ history of 
rMDD. No significant differences in stimulated levels of IL-1β (A), IL-6 (B), IL-10 (C) 
or IL-33 (D) were detected based on participants’ history of rMDD. Bars represent the 
mean and standard error of the mean (SEM). 
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Figure 5. Levels of anhedonia and IL-33. Greater levels of current anhedonia symptoms 
were significantly associated with higher stimulated levels of IL-33. 
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Figure 6. Schematic of the experimental design and timeline for Study 2. 
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Figure 7. Time course and stressors for the chronic escalating stress (CES) paradigmused 
in Studies 2 and 3. Animals in the acute footshock condition (AFS) remained undisturbed 
in their home cages until P39, on which they went through a single session of footshock. 
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Figure 8. Sucrose preference over time. There was a marginally significant trend for the 
between-subject effect of group on sucrose preference. Bars represent the mean and 
standard error of the mean (SEM). 
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Figure 9. Schematic of the experimental design and timeline for Study 3.  
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Figure 10. Expression of IL-1β (A), IL-6 (B), IL-10 (C), and IL-33 (D) in the NAc, VTA, 
AMG and PVN. There were no significant main effects of group or group × region 
interaction.
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Appendix A  
Study 1 Supplementary data 
Circulating cytokines. We conducted a series of ANOVAs using circulating 
levels of each of the cytokines (IL-6, IL-10, and IL-33) as a dependent variable and 
rMDD history as an independent factor among participants with no current MDD 
diagnosis (n = 37) only and the results were maintained. Specifically, there was no 
significant rMDD group differences for any of the three cytokines: IL-6, F(1, 36) = 0.81, 
p = .37, η2 = .02, IL-10, F(1, 36) = 0.24, p = .62, η2 = .01, or IL-33, F(1, 36) = 0.15, p = 
.70, η2 = .004. We also conducted the same analyses among women only (n = 34) and the 
results remained unchanged: IL-6, F(1, 33) = 0.28, p = .60, η2 = .01, IL-10, F(1, 33) = 
0.56, p = .46, η2 = .02, or IL-33, F(1, 33) = 0.27, p = .61, η2 = .008. Lastly, we excluded 
both individuals with a current MDD diagnosis and men  (n = 33) and obtained similar 
results: IL-6, F(1, 32) = 0.30, p = .59, η2 = .01, IL-10, F(1, 32) = 0.37, p = .55, η2 = .01, 
or IL-33, F(1, 32) =0.52, p = .47, η2 = .02.  
Following this, we ran a series of ANOVAs using circulating levels of each 
cytokine (IL-6, IL-10, and IL-33) as a dependent variable and rMDD, CA, and the rMDD 
× CA interaction as independent factors among participants with no current MDD 
diagnosis (n = 37). We found a significant main effect of CA history on circulating levels 
of IL-6, F(1, 36) = 4.16, p = .05, η2 = .11, but not IL-10, F(1, 36) = .001, p = .97, η2 < 
.001, or IL-33, F(1, 36) = 0.09, p = .76, η2 = .003, with participants reporting a history of 
CA exhibiting greater levels of circulating IL-6 (M = 0.03 log pg/mg) compared to 
participants with no CA history (M = 0.01 log pg/mg). The rMDD × CA interaction was 
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not significant for any of the cytokines: IL-6, F(1, 38) = 0.26, p = .61, η2 =.008, IL-10, 
F(1, 38) = 0.09, p = .76, η2 = .003, or IL-33, F(1, 38) = 1.16, p = .28, η2 = .03.  
We then conducted the same analyses among women only (n = 34).  We found no 
significant main effect of CA history on circulating levels of IL-6, F(1, 33) = 3.09, p = 
.09, η2 = .09, IL-10, F(1, 33) = .03, p = .87, η2 = .001, or IL-33, F(1, 33) = 0.29, p = .86, 
η2 = .01. The rMDD × CA interaction was not significant for any of the cytokines: IL-6, 
F(1, 33) = 0.24, p = .63, η2 = .008, IL-10, F(1, 33) = 0.22, p = .64, η2 = .007, or IL-33, 
F(1, 33) = 0.69, p = .79, η2 = .002.   
Lastly, we conducted the same analyses excluding individuals with a current 
MDD diagnosis and men (n = 33). We found no significant main effect of CA history on 
circulating levels of IL-6, F(1, 32) = 3.12, p = .09, η2 = .10, IL-10, F(1, 32) = .03, p = .87, 
η2 = .001, or IL-33, F(1, 32) = 0.03, p = .86, η2 = .01. The rMDD × CA interaction was 
not significant for any of the cytokines: IL-6, F(1, 32) = 0.18, p = .67, η2 = .006, IL-10, 
F(1, 33) = 0.22, p = .64, η2 = .007, or IL-33, F(1, 32) = 0.07, p = .79, η2 = .002. 
Stimulated cytokines. We conducted a series of ANOVAs using stimulated 
levels of each of the cytokines (IL-1β, IL-6, IL-10, and IL-33) as a dependent variable 
and rMDD history as an independent factor among participants with no current MDD 
diagnosis (n = 37) and the results were maintained. Specifically, there was no significant 
rMDD group differences for any of the cytokines: IL-1β, F(1, 36) = 0.008, p = .93, η2 < 
.001, IL-6, F(1, 36) = 0.001, p = .97, η2 < .001, IL-10, F(1, 36) = 0.55, p = .46, η2 = .02, 
or IL-33, F(1, 36) = 1.15, p = .29, η2 = .03. We also conducted the same analyses among 
women only (n = 34) and the results remained unchanged: IL-1β, F(1, 33) = 0.26, p = .62, 
η2 = .008, IL-6, F(1, 33) = 0.38, p = .54, η2 = .01, IL-10, F(1, 33) = 1.11, p = .30, η2 = 
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.03, or IL-33, F(1, 33) = 2.50, p = .12, η2 = .07. Lastly, we excluded both individuals with 
a current MDD diagnosis and men  (n = 33) and obtained similar results: IL-1β, F(1, 32) 
= 0.06, p = .81, η2 = .002, IL-6, F(1, 32) = 0.14, p = .71, η2 =.004, IL-10, F(1, 32) = 0.98, 
p = .33, η2 = .03, or IL-33, F(1, 32) = 1.83, p = .19, η2 = .06.  
Following this, we ran a series of ANOVAs using stimulated levels of each 
cytokine (IL-1β, IL-6, IL-10, and IL-33) as a dependent variable and rMDD, CA, and the 
rMDD × CA interaction as independent factors among participants with no current MDD 
diagnosis (n = 37). We found no significant main effect of CA history on stimulated 
levels of IL-1β, F(1, 36) = 0.07, p = .79, η2 = .002, IL-6, F(1, 36) = .41, p = .52, η2 = .01, 
IL-10, F(1, 36) = 0.03, p = .86, η2 = .001, or IL-33, F(1, 36) = 0.002, p = .97, η2 < .001.  
In addition, the rMDD × CA interaction was not significant for any of the cytokines: IL-
1β, F(1, 36) = 0.71, p = .41, η2 = .02, IL-6, F(1, 36) = 2.16, p = .15, η2 = .06, IL-10, F(1, 
36) = 0.47, p = .49, η2 = .01, or IL-33, F(1, 36) = 1.16, p = .29, η2 = .03.  
We then conducted the same analyses among women only (n = 34).  We found no 
significant main effect of CA history on stimulated levels of IL-1β, F(1, 33) = 0.36, p = 
.55, η2 = .01, IL-6, F(1, 33) = 1.32, p = .26, η2 = .04, IL-10, F(1, 33) = 0.01, p = .92, η2 < 
.001, or IL-33, F(1, 33) = 0.18, p = .68, η2 <=.006.  In addition, the rMDD × CA 
interaction was not significant for any of the cytokines: IL-1β, F(1, 33) = 0.51, p = .48, η2 
= .02, IL-6, F(1, 33) = 2.27, p = .14, η2 = .07, IL-10, F(1, 33) = 0.46, p = .50, η2 = .01, or 
IL-33, F(1, 33) = 0.52, p = .48, η2 = .02.  
Lastly, we conducted the same analyses excluding individuals with a current 
MDD diagnosis and men (n = 33). Again, the results remained unchanged, as we found 
no significant main effect of CA history on stimulated levels of IL-1β, F(1, 32) = 0.17, p 
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= .69, η2 = .006, IL-6, F(1, 32) = 0.92, p = .03, η2 = .04, IL-10, F(1, 32) = 0.04, p = .95, 
η2 < .001, or IL-33, F(1, 32) = 0.06, p = .81, η2 = .002.  In addition, the rMDD × CA 
interaction was not significant for any of the cytokines: IL-1β, F(1, 32) = 0.86, p = .36, η2 
= .03, IL-6, F(1, 32) = 2.98, p = .09, η2 = .09, IL-10, F(1, 32) = 0.49, p = .50, η2 = .02, or 
IL-33, F(1, 32) = 0.80, p = .38, η2 = .03.  
Exploratory analyses. By way of testing the exploratory aim (1d), we examined 
whether levels of anhedonia, assessed using MASQ –AD subscale, were associated with 
increased circulating levels of cytokines. Specifically, we conducted exploratory 
correlations analyses using other circulating (n = 1) and stimulated (n = 10) cytokines on 
the panel in addition to IL-1β, IL-6, IL-10, and IL-33. All of the circulating IFNγ levels 
were below the detection limit and were thus excluded from the analyses. The 
percentages of the values for other circulating cytokine levels that were below the 
detection limit of our assay were as follows: IL-4 (33.3%), IL17A (69.2%), IL17F 
(97.4%), IL-21 (94.9%), IL-22 (74.4%), IL-23 (94.9%), IL-25 (82.1%), IL-31 (89.7%), 
and sCD40L (97.4%). These cytokines were, therefore, excluded from our analyses as 
well. We found no significant associations between current anhedonia symptoms and 
circulating levels of the remaining TNFα, r(39) = 0.005, p = .97. 
In relation to stimulated cytokine levels, we excluded IL-4 from the analyses due 
to high percented of values that were below the detection limit (97.4%). We found 
significant associations between anhedonia and stimulated levels of IL-17A, r(37) = .39, 
p = .01, IL-17F, r(37) = .36, p = .02, IL-21, r(37) = 0.44, p = .005, IL-22, r(37) = .33, p = 
.04, IL-23, r(37) = .33, p = .04, IL-25, r(37) = .40, p = .01, IL-31, r(37) = .38, p = .02, 
IFNγ, r(37) = .33, p = .04, and sCDL40 cells, r(37) = .43, p = .007 (Supplementary  
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Figure 1), but not TNFα, r(39) = .25, p = .13. Notably, the results remained largely 
unchanged when we statistically controlled for participants’ age, sex, ethnicity, income, 
body mass index (BMI), body temperature, time of sample collection, or lifetime 
smoking (Supplementary Table 1).  
We conducted similar analyses among to examine the association between current 
anhedonia levels and stimulated Th-17 cytokine levels among participants with no 
current MDD diagnosis (n = 37). We found significant associations between anhedonia 
and stimulated levels of IL-17A, r(35) = .34, p = .04, IL-21, r(35) = 0.38, p = .02, IL-25, 
r(35) = .33,  p = .05, IL-31, r(35) = .33, p = .04,  p = .04, and sCDL40 cells, r(35) = .37, p 
= .02, but not  IL-17F, r(35) = .29, p = .08, IL-22, r(35) = .29, p = .09, IL-23, r(35) = .29, 
p = .08, IFNγ, r(35) = .24,  p = .16, or  TNFα, r(35) = .19, p = .26. 
We then conducted the same analyses among women only (n = 34). We found 
significant associations between anhedonia and stimulated levels of IL-17A, r(33) = .41, 
p = .02, IL-17F, r(33) = .39, p = .02, IL-21, r(33) = 0.48, p = .004, IL-22, r(33) = .36, p = 
.04, IL-23, r(33) = .39, p = .02, IL-25, r(33) = .44,  p = .009, IL-31, r(33) = .42, p = .01, 
IFNγ, r(33) = .41,  p = .02, and sCDL40 cells, r(33) = .46, p = .007, but not  TNFα, r(33) 
= .29, p = .10. 
Lastly, we conducted the same analyses excluding individuals with a current 
MDD diagnosis and men (n = 33). We found significant associations between anhedonia 
and stimulated levels of IL-17A, r(32) = .37, p = .03, IL-21, r(32) = 0.43, p = .01, IL-23, 
r(32) = .35, p = .05, IL-25, r(32) = .37,  p = .03, IL-31, r(32) = .38, p = .03,  p = .04, and 
sCDL40 cells, r(32) = .41, p = .02, but not  IL-17F, r(32) = .33, p = .06, IL-22, r(32) = 
.32, p = .07, IFNγ, r(32) = .33,  p = .06, or  TNFα, r(32) = .21, p = .23. 
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Additionally, we found significant associations between current depressive 
symptoms and stimulated levels of IL-17A, r(37) = .33, p = .04, IL-17F, r(37) = .31, p = 
.05, IL-21, r(37) = .36, p = .02, IL-25, r(37) = .34, p = .04, IL-31, r(37) = .38, p = .02, 
IFNγ, r(37) = .31, p = .05, and sCDL40 cells, r(37) = .34, p = .03, but not IL-22, r(37) = 
.23, p = .13, IL-23, r(37) = .31, p = .06, or TNFα, r(37) = .26, p = .11. 
Study 2 Supplementary data 
To examine the potential impact of adolescent life stress on sucrose and water 
consumption separately, as opposed to sucrose preference, we conducted a 6 (time: 0.5h, 
1h, 2h, 4h, 8h, and 16h) × 4 (group: CES+LPS, AFS+LPS, NS+LPS, and NS+Veh) 
repeated measures ANOVA separately for sucrose and water consumption values 
normalized by body weight. We found a significant main effect of time, F(5,140) = 
139.89, p <.001, η2 = .83 and time × group interaction, F(15,140) = 3.24, p <.001, η2 = 
.26, on sucrose consumption. There was no significant between-subject effect of group, 
F(3,28) = 2.12, p = .12, η2 = .18. Post hoc analysis revealed that IL-6 expression was 
significantly lower in the NAc compared to the VTA, p = .12 and PVN, p = .004, with no 
differences between any other groups (lowest p = .08). When we broke this interaction 
down to examine its form and conducted separate analyses for each timepoint, we found 
that group effect on sucrose consumption was significant 8h following LPS 
administration, F(3,31) = 3.52, p = .03, η2 = .27, but not at any other timepoint (lowest p 
= .14).  
Post hoc analysis showed that 8h following an immune challenge, rats in the NS+Veh 
consumed significantly more sucrose compared to animals in NS+LPS, p = .01, 
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CES+LPS, p = .03, or  AFS+LPS, p = .01, groups (Supplementary Figure 2). There were 
no significant differences between any other groups, (lowest p = .70). 
We conducted similar analysis using water consumption as a dependent variable. We 
found a significant main effect of time, F(5,140) = 26.85, p <.001, η2 = .49 and a 
significant time × group interaction, F(15,140) = 1.88, p =.03, η2 = .17. There was no 
significant between-subject effect of group, F(15,140) = 0.92, p =.44, η2 = .09. When we 
conducted separate analyses for each timepoint, we found that no significant group effect 
on water consumption at any of the six timeponts (lowest p = .18).  
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Supplementary Table 1. Results of the partial correlation analysis (r-values) between 
participants’ current anhedonia levels and stimulated cytokines, controlling for various 
demographic and physiological factors.  
  Current Anhedonia Levels 
Controlling 
for: Age  Sex Income Ethnicity BMI BT TOD Smoking 
Cytokine:        
        
IL-17A .35* .38* .35* .39* .40** .39* .41** .36* 
  
IL-17F .32* .36* .34* .37* .38* .36* .40** .34* 
  
IL-21 .39* .44** .40** .45** .45** .44** .47** .44** 
  
IL-22 .31 .33* .28 .32* .35* .33* .37* .29 
  
IL-23 .26 .33* .30 .33* .34* .33* .34* .37* 
  
IL-25 .36* .40* .38* .42** .42** .40** .43** .39* 
  
IL-31 .36* .38* .34* .40** .39* .38* .42** .36* 
  
IFNγ .30 .33* .29 .31* .33* .33* .32* .31 
  
sCDL40  .41** .43** .41** .44** .44** .43** .46** .38* 
                  
Note. *p < .05. **p < .01 Degrees of freedom for all analyses = 36 
BMI = Body Mass Index; BT = body temperature; TOD = time of day 
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Supplementary Figure 1. Levels of anhedonia symptoms and stimulated cytokines. 
 Levels of current anhedonia were significantly associated with stimulated levels of IL  
17A (A), IL-17F (B), IL-21(C), IL-22 (D), IL-23 (E), IL-25 (F), IL-31 (G), IFNγ (H), and  
sCD40L (I) cells. 
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Supplementary Figure 2. Sucrose (A) and water (B) consumption time course during 
the sucrose preference test. Rats in the NS+Veh group consumed significantly more 
sucrose compared to animals in any other group 8h following the systemic administration 
of the LPS. There were no significant group differences in water consumption at any of 
the timepoints. 
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Supplementary Figure 3. GAPDH gene expression in the NAc (A), VTA (B), AMG 
(C), and PVN (D). There was a significant effect of group on GAPDH in the AMG. Thus, 
we used non-normalized data for all analysis for that region. There was no significant 
effect of group in any of the other brain regions. 
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